234 related articles for article (PubMed ID: 26004580)
1. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
[TBL] [Abstract][Full Text] [Related]
2. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
[TBL] [Abstract][Full Text] [Related]
3. Cystamine and Disulfiram Inhibit Human Transglutaminase 2 via an Oxidative Mechanism.
Palanski BA; Khosla C
Biochemistry; 2018 Jun; 57(24):3359-3363. PubMed ID: 29570977
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase as a therapeutic target for celiac disease.
Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
[TBL] [Abstract][Full Text] [Related]
5. Cinnamoyl inhibitors of tissue transglutaminase.
Pardin C; Pelletier JN; Lubell WD; Keillor JW
J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
Hausch F; Halttunen T; Mäki M; Khosla C
Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
[TBL] [Abstract][Full Text] [Related]
7. Role of transglutaminase 2 in celiac disease pathogenesis.
Klöck C; Diraimondo TR; Khosla C
Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
[TBL] [Abstract][Full Text] [Related]
8. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Song M; Hwang H; Im CY; Kim SY
J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
[TBL] [Abstract][Full Text] [Related]
9. Activation and inhibition of transglutaminase 2 in mice.
Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.
Klöck C; Herrera Z; Albertelli M; Khosla C
J Med Chem; 2014 Nov; 57(21):9042-64. PubMed ID: 25333388
[TBL] [Abstract][Full Text] [Related]
11. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.
Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M
Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735
[TBL] [Abstract][Full Text] [Related]
12. Thioredoxin-1 Selectively Activates Transglutaminase 2 in the Extracellular Matrix of the Small Intestine: IMPLICATIONS FOR CELIAC DISEASE.
Plugis NM; Palanski BA; Weng CH; Albertelli M; Khosla C
J Biol Chem; 2017 Feb; 292(5):2000-2008. PubMed ID: 28003361
[TBL] [Abstract][Full Text] [Related]
13. Dihydroisoxazole analogs for labeling and visualization of catalytically active transglutaminase 2.
Dafik L; Khosla C
Chem Biol; 2011 Jan; 18(1):58-66. PubMed ID: 21276939
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
[TBL] [Abstract][Full Text] [Related]
15. A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in H9c2 cells: A role in cell survival.
Vyas FS; Hargreaves AJ; Bonner PL; Boocock DJ; Coveney C; Dickenson JM
Biochem Pharmacol; 2016 May; 107():41-58. PubMed ID: 27005940
[TBL] [Abstract][Full Text] [Related]
16. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase.
van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD
Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043
[TBL] [Abstract][Full Text] [Related]
17. β
Vyas FS; Nelson CP; Freeman F; Boocock DJ; Hargreaves AJ; Dickenson JM
Eur J Pharmacol; 2017 Oct; 813():105-121. PubMed ID: 28754379
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the development of tissue transglutaminase (TG2) inhibitors.
Badarau E; Collighan RJ; Griffin M
Amino Acids; 2013 Jan; 44(1):119-27. PubMed ID: 22160259
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors.
Fell S; Wang Z; Blanchard A; Nanthakumar C; Griffin M
Amino Acids; 2021 Feb; 53(2):205-217. PubMed ID: 33474654
[TBL] [Abstract][Full Text] [Related]
20. Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.
Munezane T; Hasegawa T; Suritala ; Tanaka A; Okada K; Okita Y
J Vasc Surg; 2010 Oct; 52(4):967-74. PubMed ID: 20615646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]